End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,907 INR | -0.71% | -3.25% | +13.62% |
May. 22 | Metropolis Healthcare Limited to Seek Acquisitions | CI |
May. 22 | Transcript : Metropolis Healthcare Limited, Q4 2024 Earnings Call, May 22, 2024 |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- With an expected P/E ratio at 72.27 and 54.7 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.62% | 1.17B | B+ | ||
-24.25% | 7.76B | B+ | ||
+68.65% | 4.33B | C+ | ||
-2.98% | 2.64B | - | ||
+2.78% | 2.63B | B- | ||
-46.17% | 2.16B | B- | ||
-15.27% | 1.75B | C- | ||
-22.12% | 1.46B | A- | ||
-43.81% | 1.14B | C+ | ||
+18.81% | 999M | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- METROPOLIS Stock
- Ratings Metropolis Healthcare Limited